Chronic hepatitis B market to reach US$3.2b by 2034: report

This comes as new CHB functional cures are expected to arrive.

The chronic hepatitis B (CHB) therapeutics market size in seven pharmaceutical markets is expected to reach US$3.2b ($4.147b) by 2034, according to GlobalData.

This is amidst the CHB therapeutics market is currently dominated by nucleostide analogues, entecavir, Vemlidy, and tenofovir disoproxil fumarate, but there are no CHB products in late-stage development, it said in its CHB Seven-Market Forecast.

The seven markets are the US, France, Germany, Italy, Spain, the UK, and Japan.

The market size stood at US$1.5b ($1.9b) in 2024, it added. It also expects the sector to gain a 7.9% Compound Annual Growth Rate (CAGR) between 2024 and 2034.

Five late-stage products are currently in late-stage development and are expected to launch by 2034, GlobalData said.

These include GSK’s receptor 8 agonist, bepirovirsen, Gilead Sciences’ TLR8 agonist, selgantolimod, GSK’s small interfering RNA, daplusiran + tomligisiran, Aligos Therapeutics’ capsid protein inhibitor, ALG-000184, and Arbutus Biopharma’s hepatitis B virus surface antigen inhibitor, imdusiran, it added.

The products will be used as monotherapy or in combination with existing drugs to achieve a functional cure for CHB patients.

However, projected reductions in the diagnosed prevalent cases of CHB are expected to curtail market growth, GlobalData said.